<?xml version='1.0' encoding='utf-8'?>
<document id="27029796"><sentence text="Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer."><entity charOffset="0-9" id="DDI-PubMed.27029796.s1.e0" text="Sorafenib" /></sentence><sentence text="In this investigation, we test the hypothesis that treatment with sorafenib, an anti-angiogenic agent, decreases tumor vascularization and, consequently, hinders the delivery of monoclonal antibodies (mAb) to xenograft tumors"><entity charOffset="66-75" id="DDI-PubMed.27029796.s2.e0" text="sorafenib" /></sentence><sentence text=" Severe combined immunodeficiency mice bearing carcinoembryonic antigen (CEA) expressing tumor xenografts were divided into control and sorafenib-treated groups"><entity charOffset="136-145" id="DDI-PubMed.27029796.s3.e0" text="sorafenib" /></sentence><sentence text=" Sorafenib was administered to the latter group at 50 mg/kg IP every 48 h, starting 4 days post-tumor implantation"><entity charOffset="1-10" id="DDI-PubMed.27029796.s4.e0" text="Sorafenib" /></sentence><sentence text=" When tumors attained a size of 200-300 mm(3), mice were evaluated for (a) tumor microvessel density (using immunohistochemical analysis), (b) tumor macromolecular extravasation (using Evans Blue Dye (EBD)), (c) pharmacokinetics of an anti-CEA mAb, T84" /><sentence text="66, following an intravenous dose of 10 mg/kg, and (d) intra-tumoral spatial distribution of T84" /><sentence text="66 (using autoradiography)" /><sentence text=" Sorafenib treatment resulted in a substantial reduction in tumor growth rate, a visible reduction in tumor microvessel density, and in a 46"><entity charOffset="1-10" id="DDI-PubMed.27029796.s8.e0" text="Sorafenib" /></sentence><sentence text="4% decrease in EBD extravasation in tumor tissue (p &lt; 0" /><sentence text="0455)" /><sentence text=" For control and treated mice, no significant difference was found for the area under the mAb plasma concentration-time curve (AUC(0-7d): 1" /><sentence text="67 × 10(3) ± 1" /><sentence text="28 × 10(2) vs" /><sentence text=" 1" /><sentence text="76 × 10(3) ± 1" /><sentence text="75 × 10(2) nM × day, p = 0" /><sentence text="51)" /><sentence text=" However, tumor AUC(0-7d) was reduced by 40" /><sentence text="8% in sorafenib-treated mice relative to that observed in control mice (5"><entity charOffset="6-15" id="DDI-PubMed.27029796.s19.e0" text="sorafenib" /></sentence><sentence text="61 × 10(2) ± 4" /><sentence text="27 × 10(1) vs" /><sentence text=" 9" /><sentence text="48 × 10(2) ± 5" /><sentence text="61 × 10(1) nM × day, p &lt; 0" /><sentence text="001)" /><sentence text=" Sorafenib therapy was also found to markedly alter mAb tumor spatial distribution"><entity charOffset="1-10" id="DDI-PubMed.27029796.s26.e0" text="Sorafenib" /></sentence><sentence text=" The results collectively suggest that sorafenib treatment causes a significant reduction in mAb delivery to, and distribution within, solid tumors"><entity charOffset="39-48" id="DDI-PubMed.27029796.s27.e0" text="sorafenib" /></sentence><sentence text="" /></document>